Procuritas partners with Nordic Biomarker
Procuritas Capital Investors (“Procuritas”) is pleased to announce that it has taken a majority stake in Nordic Biomarker, a fast-growing Swedish supplier of advanced reagents for IVD coagulation analyzers with a clear sustainability-driven purpose.
Nordic Biomarker was founded in 2007 to meet market demand for an independent OEM-supplier of high-quality reagents for coagulation analyzers. The company has a growing product portfolio of routine and specialty reagents for IVD coagulation testing. In 2017, Nordic Biomarker teamed up with Medirox, adding CE-marked reagent kits to the product offering. Products are delivered to clients around the world for sale under their own brand names as well as to distributors of its portfolio of Medirox branded kits. Production is performed in-house at Nordic Biomarker’s new facilities in Umeå and in Linköping, Sweden. Nordic Biomarker is investing significantly in research and development of new products and has several new products in pipeline. The company had revenue of 131M SEK in 2021 and has approximately 80 employees.
Procuritas has a strong track record of investing in companies that have the potential for transformational growth, in this instance to grow from a niche leader to a global challenger in coagulation testing through organic growth as well as M&A. The investment in Nordic Biomarker aligns with Procuritas’ target to support the UN Sustainable Development Goals and fits in with #3 “To ensure healthy lives and promote well-being at all ages”.
Rikard Rodén, CEO, commented: “We are really proud to be partnering with Procuritas who have a fantastic track record of supporting businesses on their growth journey and making sure their potential is realized. We have built up a great partnership over the past months and really look forward to working together.”
Johan Conradsson, Co-Managing Partner at Procuritas, commented: “With our ageing population and the trend towards science-based health testing, we see great opportunities for Nordic Biomarker to continue its impressive journey. The company has high-quality products for patients and holds a unique and competitive position in a growing market. We see a great future for this business.”